Katherine Xie and Angela Yu; bio-specimen processing at the Anlyan Center.
The Program of Applied Translational Research (PATR) is dedicated to the process of applying discoveries generated in the laboratory and in preclinical experiments, to the development of clinical studies, and to the design of clinical trials. As a critical component of this mission, the Program also seeks to conduct translational research to advance the mechanistic understanding of novel biomarkers to enhance their clinical utility in complex diseases. Our multidisciplinary team is comprised of talented physicians and scientists committed to patient-oriented research and developing solutions in clinical medicine and disease management in the community. The Program aims to combine the creativity, commitment, experience, and skills of our physician-scientists to improve the care of our patients.
This is a multicenter prospective observational study sponsored by the NHLBI to investigate novel biomarkers in the detection of early AKI after major cardiac surgery.
The shortage of kidneys for transplantation is a major dilemma, which has driven efforts to expand the organ supply by using kidneys from deceased donors with risk factors for allograft...
Type 2 diabetes is a major public health problem worldwide. Progressive chronic kidney disease (CKD) in type 2 diabetes is associated with significant morbidity and mortality.
Renal dysfunction is a common complication in hospitalized patients with cirrhosis. The diagnosis of Type 1 HRS is one of exclusion and cannot be made until other causes of renal failure,...
The ASsessment, Serial Evaluation, and Subsequent Sequelae in Acute Kidney Injury (ASSESS-AKI) Network
The ASsessment, Serial Evaluation, and Subsequent Sequelae in Acute Kidney Injury (ASSESS-AKI) Network is an epidemiological study of long term outcomes following episodes of AKI.
The overall objective of the scientific aspect of this project is to better define cardio-renal phenotypes and their prognostic importance in HF.
The PRESERVE trial (Prevention of Serious Adverse Events Following Angiography) is a multicenter VA Healthcare System study that is helmed by Steven Weisbord, MD, MSc and Paul Palevsky, MD,...